Cerevel Therapeutics Holdings Key Executives
This section highlights Cerevel Therapeutics Holdings's key executives, including their titles and compensation details.
Find Contacts at Cerevel Therapeutics Holdings
(Showing 0 of )
Cerevel Therapeutics Holdings Earnings
This section highlights Cerevel Therapeutics Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2023 | 2023-11-01 | $-0.63 | $-0.61 |
| Read Transcript | Q2 | 2023 | 2023-08-02 | $-0.65 | $-0.63 |
| Read Transcript | Q1 | 2023 | 2023-05-07 | N/A | N/A |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
$44.96
Stock Price
$8.19B
Market Cap
334
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Cerevel Therapeutics Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $5.63M | $4.90M | $2.73M | $397.00K | $- |
| Gross Profit | $-5.63M | $-4.90M | $-2.73M | $-397.00K | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $334.64M | $280.26M | $161.85M | $103.30M | $50.29M |
| General and Administrative Expenses | $112.62M | $87.59M | $58.24M | $45.81M | $33.17M |
| Selling and Marketing Expenses | $-5.63M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $112.62M | $87.59M | $58.24M | $45.81M | $33.17M |
| Other Expenses | $- | $6.88M | $-5.39M | $-3.27M | $9.00K |
| Operating Expenses | $465.64M | $367.85M | $220.10M | $149.12M | $83.46M |
| Cost and Expenses | $465.64M | $367.85M | $220.10M | $149.12M | $83.46M |
| Interest Income | $43.87M | $9.62M | $157.00K | $224.00K | $1.55M |
| Interest Expense | $10.57M | $9.62M | $- | $- | $- |
| Depreciation and Amortization | $5.63M | $4.90M | $2.73M | $397.00K | $177.00K |
| EBITDA | $-441.64M | $-367.85M | $-211.98M | $-148.72M | $-36.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-447.26M | $-367.85M | $-220.10M | $-149.12M | $-83.46M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $14.93M | $16.50M | $-5.24M | $-3.05M | $-44.88M |
| Income Before Tax | $-432.34M | $-351.35M | $-225.33M | $-152.17M | $-128.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $503.00K | $160.00K | $-2.89M | $-24.00K | $45.00K |
| Net Income | $-432.84M | $-351.51M | $-222.45M | $-152.14M | $-128.39M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.67 | $-2.32 | $-1.63 | $-2.07 | $-1.01 |
| EPS Diluted | $-2.67 | $-2.32 | $-1.63 | $-2.07 | $-1.01 |
| Weighted Average Shares Outstanding | 162.06M | 151.27M | 136.58M | 73.64M | 127.12M |
| Weighted Average Shares Outstanding Diluted | 162.06M | 151.27M | 136.58M | 73.64M | 127.12M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $8.25M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $1.54M | $1.50M | $1.45M | $1.35M | $1.32M | $1.29M | $1.27M | $1.22M | $1.12M | $1.64M | $980.00K | $601.00K | $63.00K | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $-1.54M | $6.74M | $-1.45M | $-1.35M | $-1.32M | $-1.29M | $-1.27M | $-1.22M | $-1.12M | $-1.64M | $-980.00K | $-601.00K | $-63.00K | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 81.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $106.42M | $97.13M | $85.25M | $74.08M | $78.18M | $81.31M | $71.39M | $72.54M | $55.02M | $47.84M | $40.16M | $37.29M | $36.56M | $30.14M | $24.03M | $22.18M | $26.96M | $21.97M | $17.34M | $7.01M |
| General and Administrative Expenses | $36.23M | $42.44M | $26.05M | $22.76M | $21.37M | $25.93M | $23.68M | $20.47M | $17.51M | $16.65M | $14.37M | $13.22M | $14.01M | $11.76M | $10.34M | $12.97M | $10.74M | $14.43M | $9.64M | $5.32M |
| Selling and Marketing Expenses | $- | $-1.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $36.23M | $40.93M | $26.05M | $22.76M | $21.37M | $25.93M | $23.68M | $20.47M | $17.51M | $16.65M | $14.37M | $13.22M | $14.01M | $11.76M | $10.34M | $12.97M | $10.74M | $14.43M | $9.64M | $5.32M |
| Other Expenses | $-921.00K | $-5.34M | $7.82M | $-9.77M | $-11.09M | $8.65M | $21.00K | $8.00K | $1.00K | $5.32M | $-7.54M | $-2.74M | $-425.00K | $8.70M | $-4.68M | $8.42M | $-15.71M | $- | $- | $- |
| Operating Expenses | $142.66M | $138.06M | $111.31M | $96.84M | $99.55M | $107.25M | $95.06M | $93.01M | $72.53M | $64.49M | $54.53M | $50.51M | $50.57M | $41.90M | $34.36M | $35.16M | $37.70M | $56.41M | $35.97M | $6.29M |
| Cost and Expenses | $142.66M | $139.56M | $111.31M | $96.84M | $99.55M | $107.25M | $95.06M | $93.01M | $72.53M | $64.49M | $54.53M | $50.51M | $50.57M | $41.90M | $34.36M | $35.16M | $37.70M | $56.41M | $35.97M | $6.29M |
| Interest Income | $14.46M | $15.08M | $9.89M | $9.82M | $6.44M | $5.95M | $3.99M | $667.00K | $295.00K | $119.00K | $13.00K | $10.00K | $15.00K | $14.00K | $1.00K | $5.00K | $204.00K | $192 | $368 | $475 |
| Interest Expense | $2.65M | $2.65M | $2.64M | $2.64M | $6.44M | $5.95M | $1.29M | $- | $295.00K | $119.00K | $13.00K | $10.00K | $15.00K | $14.00K | $1.00K | $5.00K | $204.00K | $- | $- | $- |
| Depreciation and Amortization | $1.54M | $1.50M | $1.45M | $1.35M | $1.32M | $1.29M | $1.27M | $1.22M | $1.12M | $1.64M | $980.00K | $601.00K | $63.00K | $61.00K | $51.00K | $190.00K | $95.00K | $10.00K | $81.00K | $60.00K |
| EBITDA | $-141.12M | $-138.06M | $-92.14M | $-95.44M | $-98.23M | $-93.35M | $-95.06M | $-91.11M | $-71.12M | $-63.40M | $-54.53M | $-50.51M | $-50.57M | $-36.34M | $-34.31M | $-34.97M | $-37.61M | $-36.39M | $-26.90M | $-12.27M |
| EBITDA Ratio | 0.00% | -1674.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-142.66M | $-139.56M | $-111.31M | $-96.84M | $-99.55M | $-107.25M | $-95.06M | $-93.01M | $-72.53M | $-64.49M | $-54.53M | $-50.51M | $-50.57M | $-41.90M | $-34.36M | $-35.16M | $-37.70M | $-36.40M | $-26.98M | $-12.33M |
| Operating Income Ratio | 0.00% | -1692.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $10.88M | $7.09M | $15.07M | $-2.58M | $-4.65M | $14.60M | $-4.87M | $2.54M | $4.24M | $5.43M | $-7.53M | $-2.73M | $-410.00K | $3.22M | $-4.68M | $5.92M | $-15.51M | $-19.82M | $-8.61M | $6.51M |
| Income Before Tax | $-131.77M | $-132.47M | $-96.24M | $-99.43M | $-104.20M | $-92.65M | $-99.94M | $-90.47M | $-68.29M | $-59.05M | $-62.06M | $-53.24M | $-50.98M | $-33.18M | $-39.05M | $-26.73M | $-53.21M | $-56.22M | $-35.60M | $-5.81M |
| Income Before Tax Ratio | 0.00% | -1606.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $138.00K | $188.00K | $123.00K | $107.00K | $85.00K | $160.00K | $4.87M | $8.00K | $-4.24M | $119.00K | $-13.00K | $-10.00K | $-15.00K | $-3.00K | $-5.00K | $-16.00K | $-204.00K | $45.00K | $- | $- |
| Net Income | $-131.91M | $-132.66M | $-96.36M | $-99.53M | $-104.29M | $-92.81M | $-104.81M | $-90.47M | $-64.06M | $-59.05M | $-62.06M | $-53.24M | $-50.98M | $-33.18M | $-39.04M | $-26.72M | $-53.21M | $-56.26M | $-35.60M | $-5.81M |
| Net Income Ratio | 0.00% | -1608.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.73 | $-0.76 | $-0.61 | $-0.63 | $-0.67 | $-0.59 | $-0.69 | $-0.61 | $-0.43 | $-0.40 | $-0.43 | $-0.42 | $-0.40 | $-0.30 | $-0.31 | $-0.21 | $-0.42 | $-0.35 | $-7.73 | $-1.26 |
| EPS Diluted | $-0.73 | $-0.76 | $-0.61 | $-0.63 | $-0.67 | $-0.59 | $-0.69 | $-0.61 | $-0.43 | $-0.40 | $-0.43 | $-0.42 | $-0.40 | $-0.30 | $-0.31 | $-0.21 | $-0.42 | $-0.35 | $-7.73 | $-1.26 |
| Weighted Average Shares Outstanding | 181.61M | 174.60M | 157.50M | 157.05M | 156.65M | 156.37M | 152.30M | 148.30M | 147.98M | 147.30M | 144.02M | 127.48M | 127.23M | 109.14M | 127.12M | 127.12M | 127.12M | 163.02M | 4.61M | 4.61M |
| Weighted Average Shares Outstanding Diluted | 181.61M | 174.60M | 157.50M | 157.05M | 156.65M | 156.37M | 152.30M | 148.30M | 147.98M | 147.30M | 144.02M | 127.48M | 127.23M | 109.14M | 127.12M | 127.12M | 127.12M | 163.02M | 4.61M | 4.61M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $990.97M | $136.52M | $193.02M | $383.62M | $79.55M |
| Short Term Investments | $574.50M | $755.51M | $372.67M | $- | $- |
| Cash and Short Term Investments | $990.97M | $892.03M | $565.69M | $383.62M | $79.55M |
| Net Receivables | $5.29M | $- | $729.00K | $- | $- |
| Inventory | $- | $-2.05M | $-729.00K | $- | $- |
| Other Current Assets | $10.68M | $13.62M | $12.33M | $6.94M | $7.53M |
| Total Current Assets | $1.01B | $905.65M | $578.02M | $390.56M | $87.08M |
| Property Plant Equipment Net | $45.77M | $49.29M | $51.70M | $48.62M | $27.49M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $187.16M | $58.13M | $52.27M | $4.20M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.43M | $4.76M | $6.93M | $1.89M | $6.24M |
| Total Non-Current Assets | $236.36M | $112.17M | $110.90M | $54.71M | $33.73M |
| Other Assets | $- | $- | $0 | $- | $- |
| Total Assets | $1.24B | $1.02B | $688.92M | $445.27M | $120.81M |
| Account Payables | $11.86M | $10.06M | $11.30M | $4.99M | $2.11M |
| Short Term Debt | $3.40M | $2.90M | $2.44M | $2.04M | $2.59M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $28.43M | $22.25M | $10.10M |
| Other Current Liabilities | $76.91M | $59.60M | $28.80M | $22.52M | $10.18M |
| Total Current Liabilities | $92.18M | $72.56M | $42.54M | $29.55M | $14.88M |
| Long Term Debt | $365.21M | $366.67M | $34.11M | $30.97M | $25.82M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $112.16M | $57.35M | $33.54M | $236.00K | $2.29M |
| Total Non-Current Liabilities | $477.37M | $424.02M | $67.65M | $31.20M | $28.11M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $569.55M | $496.58M | $110.19M | $60.75M | $42.98M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $18.00K | $16.00K | $15.00K | $13.00K | $6.00K |
| Retained Earnings | $-1.40B | $-967.75M | $-616.24M | $-390.91M | $-244.30M |
| Accumulated Other Comprehensive Income Loss | $1.77M | $3.10M | $-986.00K | $- | $- |
| Other Total Stockholders Equity | $2.07B | $1.49B | $1.20B | $775.42M | $322.12M |
| Total Stockholders Equity | $673.75M | $521.24M | $578.73M | $384.52M | $77.82M |
| Total Equity | $673.75M | $521.24M | $578.73M | $384.52M | $77.82M |
| Total Liabilities and Stockholders Equity | $1.24B | $1.02B | $688.92M | $445.27M | $120.81M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.24B | $1.02B | $688.92M | $445.27M | $120.81M |
| Total Investments | $187.16M | $813.63M | $424.94M | $4.20M | $- |
| Total Debt | $480.78M | $366.67M | $36.55M | $33.01M | $28.41M |
| Net Debt | $-510.19M | $230.15M | $-156.47M | $-350.62M | $-51.14M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | March 31, 2019 | May 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $320.44M | $990.97M | $155.72M | $175.76M | $153.82M | $136.52M | $248.60M | $138.22M | $91.76M | $193.02M | $669.68M | $327.06M | $343.29M | $383.62M | $12.81M | $17.97M | $47.54M | $79.55M | $-95.44M | $4.15M |
| Short Term Investments | $525.86M | $574.50M | $521.16M | $560.66M | $673.17M | $755.51M | $741.32M | $392.99M | $451.18M | $372.67M | $- | $- | $- | $- | $- | $- | $- | $- | $190.89M | $- |
| Cash and Short Term Investments | $846.29M | $990.97M | $676.88M | $736.43M | $826.99M | $892.03M | $989.92M | $531.21M | $542.94M | $565.69M | $669.68M | $327.06M | $343.29M | $383.62M | $12.81M | $17.97M | $47.54M | $79.55M | $95.44M | $4.15M |
| Net Receivables | $4.96M | $5.29M | $3.41M | $4.13M | $3.20M | $- | $824.00K | $981.00K | $602.00K | $729.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $384.00K |
| Inventory | $8.24M | $- | $-3.41M | $-4.13M | $-3.20M | $-2.05M | $7.58M | $6.85M | $9.71M | $-729.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $8.32M | $10.68M | $7.50M | $11.11M | $10.59M | $13.62M | $7.92M | $7.95M | $10.00M | $12.33M | $5.35M | $4.72M | $6.52M | $6.94M | $3.08M | $3.93M | $6.71M | $7.53M | $- | $869.00K |
| Total Current Assets | $859.58M | $1.01B | $687.79M | $751.67M | $840.78M | $905.65M | $998.66M | $540.14M | $553.55M | $578.02M | $675.03M | $331.78M | $349.81M | $390.56M | $15.88M | $21.89M | $54.25M | $87.08M | $95.44M | $5.41M |
| Property Plant Equipment Net | $44.60M | $45.77M | $47.19M | $48.26M | $48.44M | $49.29M | $50.53M | $51.89M | $52.66M | $51.70M | $51.98M | $51.92M | $51.78M | $48.62M | $41.35M | $34.98M | $32.69M | $27.49M | $- | $1.16M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $218.59M | $187.16M | $81.34M | $88.64M | $36.05M | $58.13M | $39.86M | $1.87M | $7.93M | $52.27M | $4.20M | $4.20M | $4.20M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.58M | $3.43M | $5.64M | $5.78M | $5.08M | $4.76M | $4.66M | $2.76M | $4.41M | $6.93M | $2.27M | $3.10M | $2.31M | $6.09M | $9.81M | $5.01M | $7.09M | $6.24M | $-95.44M | $180.00K |
| Total Non-Current Assets | $267.77M | $236.36M | $134.18M | $142.68M | $89.56M | $112.17M | $95.05M | $56.52M | $65.00M | $110.90M | $58.45M | $59.22M | $58.29M | $54.71M | $51.15M | $39.99M | $39.79M | $33.73M | $-95.44M | $1.34M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $0 | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.13B | $1.24B | $821.96M | $894.35M | $930.35M | $1.02B | $1.09B | $596.66M | $618.55M | $688.92M | $733.48M | $391.00M | $408.10M | $445.27M | $67.04M | $61.88M | $94.04M | $120.81M | $- | $6.74M |
| Account Payables | $10.84M | $11.86M | $11.54M | $9.39M | $7.32M | $10.06M | $14.97M | $11.01M | $8.18M | $11.30M | $5.45M | $4.99M | $7.75M | $4.99M | $4.82M | $8.88M | $8.31M | $2.11M | $- | $2.36M |
| Short Term Debt | $3.52M | $3.40M | $3.28M | $3.15M | $3.03M | $2.90M | $2.79M | $2.67M | $2.56M | $2.44M | $2.33M | $2.24M | $2.14M | $- | $2.21M | $- | $- | $- | $- | $466.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $466.00K |
| Deferred Revenue | $-3.52M | $- | $- | $- | $- | $- | $- | $42.17M | $- | $28.43M | $22.59M | $21.70M | $24.10M | $22.25M | $21.84M | $- | $- | $- | $- | $366.00K |
| Other Current Liabilities | $69.75M | $76.91M | $64.02M | $53.02M | $52.61M | $59.60M | $42.26M | $43.06M | $24.57M | $28.80M | $23.02M | $22.04M | $24.26M | $24.55M | $22.18M | $13.89M | $14.61M | $12.77M | $- | $-914.00K |
| Total Current Liabilities | $84.10M | $92.18M | $78.84M | $65.56M | $62.96M | $72.56M | $60.02M | $56.74M | $35.32M | $42.54M | $30.80M | $29.26M | $34.15M | $29.55M | $29.21M | $22.77M | $22.91M | $14.88M | $- | $2.75M |
| Long Term Debt | $364.79M | $365.21M | $365.61M | $365.98M | $366.34M | $366.67M | $366.95M | $32.69M | $33.41M | $34.11M | $34.75M | $32.91M | $32.95M | $30.97M | $29.52M | $25.04M | $25.54M | $25.82M | $- | $43.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $43.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $114.00M | $112.16M | $104.56M | $112.31M | $69.34M | $57.35M | $63.38M | $54.41M | $28.33M | $33.54M | $38.85M | $34.95M | $965.00K | $236.00K | $-24.28M | $9.78M | $18.00M | $2.29M | $- | $- |
| Total Non-Current Liabilities | $478.78M | $477.37M | $470.16M | $478.29M | $435.68M | $424.02M | $430.33M | $87.10M | $61.73M | $67.65M | $73.60M | $67.86M | $33.92M | $31.20M | $38.58M | $34.82M | $43.54M | $28.11M | $- | $86.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.67M |
| Total Liabilities | $562.89M | $569.55M | $549.00M | $543.85M | $498.64M | $496.58M | $490.35M | $143.84M | $97.05M | $110.19M | $104.40M | $97.12M | $68.07M | $60.75M | $67.78M | $57.59M | $66.45M | $42.98M | $- | $5.50M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $267.25K | $245.88M | $245.88M | $- | $177.07M | $- |
| Common Stock | $18.00K | $18.00K | $16.00K | $16.00K | $16.00K | $16.00K | $16.00K | $15.00K | $15.00K | $15.00K | $15.00K | $13.00K | $13.00K | $13.00K | $137.59M | $1 | $- | $6.00K | $- | $2.71M |
| Retained Earnings | $-1.53B | $-1.40B | $-1.27B | $-1.17B | $-1.07B | $-967.75M | $-874.95M | $-775.01M | $-684.54M | $-616.24M | $-557.19M | $-495.13M | $-441.89M | $-390.91M | $-3.12M | $-324.22M | $-297.51M | $-244.30M | $- | $-338.04M |
| Accumulated Other Comprehensive Income Loss | $-1.09M | $1.77M | $1.68M | $1.14M | $3.69M | $3.10M | $5.19M | $7.99M | $-1.33M | $-986.00K | $-533.00K | $- | $0 | $- | $-267.25K | $0 | $- | $- | $-77.38M | $794.00K |
| Other Total Stockholders Equity | $2.10B | $2.07B | $1.54B | $1.52B | $1.50B | $1.49B | $1.47B | $1.22B | $1.21B | $1.20B | $1.19B | $789.00M | $781.91M | $775.42M | $-411.62M | $82.64M | $79.21M | $322.12M | $- | $335.77M |
| Total Stockholders Equity | $564.46M | $673.75M | $272.96M | $350.50M | $431.71M | $521.24M | $603.36M | $452.81M | $521.50M | $578.73M | $629.08M | $293.89M | $340.04M | $384.52M | $-747.00K | $4.29M | $27.59M | $77.82M | $99.69M | $1.24M |
| Total Equity | $564.46M | $673.75M | $272.96M | $350.50M | $431.71M | $521.24M | $603.36M | $452.81M | $521.50M | $578.73M | $629.08M | $293.89M | $340.04M | $384.52M | $-747.00K | $4.29M | $27.59M | $77.82M | $99.69M | $1.24M |
| Total Liabilities and Stockholders Equity | $1.13B | $1.24B | $821.96M | $894.35M | $930.35M | $1.02B | $1.09B | $596.66M | $618.55M | $688.92M | $733.48M | $391.00M | $408.10M | $445.27M | $67.04M | $61.88M | $94.04M | $120.81M | $99.69M | $6.74M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.13B | $1.24B | $821.96M | $894.35M | $930.35M | $1.02B | $1.09B | $596.66M | $618.55M | $688.92M | $733.48M | $391.00M | $408.10M | $445.27M | $67.04M | $61.88M | $94.04M | $120.81M | $99.69M | $6.74M |
| Total Investments | $744.45M | $187.16M | $521.16M | $560.66M | $673.17M | $813.63M | $781.18M | $392.99M | $459.11M | $424.94M | $4.20M | $4.20M | $4.20M | $- | $- | $- | $- | $- | $190.89M | $- |
| Total Debt | $368.30M | $480.78M | $365.61M | $365.98M | $366.34M | $366.67M | $369.74M | $35.36M | $35.97M | $36.55M | $37.09M | $35.14M | $35.09M | $33.01M | $31.72M | $25.04M | $25.54M | $25.82M | $- | $43.00K |
| Net Debt | $47.87M | $-510.19M | $209.88M | $190.22M | $212.53M | $230.15M | $121.14M | $-102.86M | $-55.79M | $-156.47M | $-632.59M | $-291.92M | $-308.20M | $-350.62M | $18.91M | $7.07M | $-22.00M | $-53.73M | $95.44M | $-4.11M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-432.84M | $-351.51M | $-225.33M | $-152.14M | $-128.39M |
| Depreciation and Amortization | $5.63M | $4.90M | $2.73M | $397.00K | $177.00K |
| Deferred Income Tax | $-2.04M | $- | $3.88M | $3.27M | $46.44M |
| Stock Based Compensation | $69.41M | $38.78M | $23.94M | $10.52M | $8.31M |
| Change in Working Capital | $16.11M | $28.06M | $15.54M | $17.71M | $343.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $2.04M | $-763.00K | $7.28M | $1.42M | $607.00K |
| Other Working Capital | $14.08M | $28.83M | $8.26M | $16.29M | $-264.00K |
| Other Non Cash Items | $1.43M | $-13.42M | $694.00K | $2.44M | $2.40M |
| Net Cash Provided by Operating Activities | $-342.30M | $-293.19M | $-178.55M | $-117.80M | $-70.72M |
| Investments in Property Plant and Equipment | $-3.81M | $-3.95M | $-10.50M | $-18.89M | $-1.10M |
| Acquisitions Net | $-77.53K | $384.88K | $- | $- | $- |
| Purchases of Investments | $-865.27M | $-887.74M | $-425.16M | $- | $- |
| Sales Maturities of Investments | $942.80M | $502.86M | $- | $- | $- |
| Other Investing Activities | $77.53K | $-384.88K | $-425.16K | $- | $- |
| Net Cash Used for Investing Activities | $73.72M | $-388.83M | $-435.66M | $-18.89M | $-1.10M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $517.50M | $251.31M | $328.25M | $5.53M | $60.06M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $548.62M | $623.19M | $423.60M | $440.83M | $60.06M |
| Net Cash Used Provided by Financing Activities | $548.62M | $623.19M | $423.60M | $440.83M | $60.06M |
| Effect of Forex Changes on Cash | $548.75M | $- | $- | $- | $- |
| Net Change in Cash | $98.94M | $-58.83M | $-190.60M | $304.14M | $-11.76M |
| Cash at End of Period | $990.97M | $138.39M | $197.22M | $387.82M | $83.68M |
| Cash at Beginning of Period | $892.03M | $197.22M | $387.82M | $83.68M | $95.44M |
| Operating Cash Flow | $-342.30M | $-293.19M | $-178.55M | $-117.80M | $-70.72M |
| Capital Expenditure | $-3.81M | $-3.95M | $-10.50M | $-18.89M | $-1.10M |
| Free Cash Flow | $-346.11M | $-297.14M | $-189.05M | $-136.69M | $-71.82M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-131.91M | $-132.66M | $7.82M | $-9.77M | $-104.29M | $-92.81M | $-99.94M | $-90.47M | $-68.29M | $-59.05M | $-62.06M | $-53.24M | $-50.98M | $-33.18M | $-39.04M | $-26.72M | $-53.21M | $-56.26M | $-35.60M | $-5.81M |
| Depreciation and Amortization | $1.54M | $1.50M | $1.45M | $1.35M | $-3.88M | $1.29M | $1.27M | $1.22M | $1.12M | $1.09M | $980.00K | $601.00K | $63.00K | $61.00K | $51.00K | $190.00K | $95.00K | $10.00K | $81.00K | $60.00K |
| Deferred Income Tax | $- | $-27.95M | $-108.50M | $-94.07M | $- | $- | $- | $- | $- | $- | $1.71M | $1.75M | $424.00K | $-8.70M | $4.68M | $-8.42M | $15.71M | $- | $- | $- |
| Stock Based Compensation | $20.93M | $25.22M | $17.09M | $14.51M | $12.59M | $10.38M | $9.70M | $10.15M | $8.56M | $6.49M | $6.13M | $5.18M | $6.14M | $657.00K | $3.47M | $3.42M | $2.97M | $4.52M | $2.70M | $797.00K |
| Change in Working Capital | $-5.18M | $8.52M | $17.33M | $879.00K | $-2.77M | $7.43M | $2.93M | $23.10M | $-5.41M | $4.26M | $3.84M | $-677.00K | $8.12M | $-33.00K | $11.29M | $1.98M | $4.47M | $-4.18M | $2.21M | $1.94M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.19M | $279.00K | $2.50M | $2.03M | $-2.77M | $-5.00M | $3.77M | $2.96M | $-2.50M | $5.40M | $389.00K | $-1.69M | $3.18M | $836.00K | $-2.72M | $-1.51M | $4.81M | $- | $- | $- |
| Other Working Capital | $-3.98M | $8.24M | $14.84M | $-1.15M | $2.77M | $12.43M | $-839.00K | $20.14M | $-2.91M | $-1.15M | $3.45M | $1.01M | $4.95M | $-869.00K | $14.01M | $3.48M | $-335.00K | $-4.18M | $2.21M | $1.94M |
| Other Non Cash Items | $-5.05M | $27.94M | $-7.82M | $9.77M | $3.42M | $-13.78M | $5.64M | $-2.12M | $-3.62M | $-5.52M | $5.62M | $776.00K | $-184.00K | $-511.00K | $-538.00K | $2.99M | $508.00K | $20.09M | $10.98M | $-5.88M |
| Net Cash Provided by Operating Activities | $-119.67M | $-97.42M | $-72.63M | $-77.33M | $-94.92M | $-87.48M | $-80.41M | $-57.66M | $-67.65M | $-52.74M | $-43.78M | $-45.61M | $-36.42M | $-41.70M | $-20.08M | $-26.56M | $-29.45M | $-35.81M | $-19.62M | $-8.90M |
| Investments in Property Plant and Equipment | $-271.00K | $-902.00K | $-513.00K | $-2.06M | $-336.00K | $-454.00K | $-171.00K | $-1.13M | $-2.20M | $-1.07M | $-1.19M | $-3.58M | $-4.66M | $-7.55M | $-7.30M | $-1.49M | $-2.56M | $-549.00K | $-193.00K | $-357.00K |
| Acquisitions Net | $- | $149.31K | $-51.91K | $-63.81K | $38.54M | $26.28K | $387.68K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-122.65M | $-317.06M | $-213.09M | $-147.49M | $-187.63M | $-174.49M | $-571.68M | $-81.32M | $-60.24M | $-425.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $142.09M | $167.75M | $265.00M | $211.30M | $298.75M | $148.21M | $184.00M | $146.75M | $23.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-149.31K | $51.91K | $63.81K | $-38.54M | $-26.28K | $-387.68K | $65.43M | $-36.34K | $-425.16K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $19.16M | $-150.21M | $51.39M | $61.75M | $110.78M | $-26.73M | $-387.85M | $64.29M | $-38.54M | $-426.23M | $-1.19M | $-3.58M | $-4.66M | $-7.55M | $-7.30M | $-1.49M | $-2.56M | $-549.00K | $-193.00K | $-357.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-75.00K | $508.37M | $1.20M | $6.36M | $1.57M | $2.34M | $243.80M | $2.32M | $2.85M | $328.25M | $387.46M | $1.83M | $742.00K | $5.53M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-75.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-23.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.47M | $508.37M | $1.20M | $37.61M | $1.44M | $2.13M | $578.64M | $39.82M | $2.60M | $2.32M | $387.58M | $32.96M | $742.00K | $420.07M | $22.29M | $-1.52M | $- | $60.00M | $- | $58.00K |
| Net Cash Used Provided by Financing Activities | $4.47M | $508.37M | $1.20M | $37.61M | $1.44M | $2.13M | $578.64M | $39.82M | $2.60M | $2.32M | $387.58M | $32.96M | $742.00K | $420.07M | $22.29M | $-1.52M | $- | $60.00M | $- | $58.00K |
| Effect of Forex Changes on Cash | $- | $53.34M | $27.86M | $-31.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-96.03M | $314.08M | $-20.04M | $22.04M | $17.30M | $-112.08M | $110.38M | $46.45M | $-103.59M | $-476.66M | $342.62M | $-16.23M | $-40.34M | $370.81M | $-5.09M | $-29.57M | $-32.01M | $23.64M | $-19.82M | $-9.20M |
| Cash at End of Period | $322.40M | $990.97M | $157.68M | $177.72M | $155.68M | $138.39M | $250.47M | $140.09M | $93.63M | $197.22M | $673.88M | $331.26M | $347.49M | $387.82M | $17.01M | $22.10M | $51.67M | $83.68M | $60.04M | $79.86M |
| Cash at Beginning of Period | $418.43M | $676.88M | $177.72M | $155.68M | $138.39M | $250.47M | $140.09M | $93.63M | $197.22M | $673.88M | $331.26M | $347.49M | $387.82M | $17.01M | $22.10M | $51.67M | $83.68M | $60.04M | $79.86M | $89.06M |
| Operating Cash Flow | $-119.67M | $-97.42M | $-72.63M | $-77.33M | $-94.92M | $-87.48M | $-80.41M | $-57.66M | $-67.65M | $-52.74M | $-43.78M | $-45.61M | $-36.42M | $-41.70M | $-20.08M | $-26.56M | $-29.45M | $-35.81M | $-19.62M | $-8.90M |
| Capital Expenditure | $-271.00K | $-902.00K | $-513.00K | $-2.06M | $-336.00K | $-454.00K | $-171.00K | $-1.13M | $-2.20M | $-1.07M | $-1.19M | $-3.58M | $-4.66M | $-7.55M | $-7.30M | $-1.49M | $-2.56M | $-549.00K | $-193.00K | $-357.00K |
| Free Cash Flow | $-119.94M | $-98.32M | $-73.14M | $-79.38M | $-95.26M | $-87.93M | $-80.58M | $-58.79M | $-69.84M | $-53.82M | $-44.96M | $-49.19M | $-41.08M | $-49.25M | $-27.38M | $-28.05M | $-32.01M | $-36.36M | $-19.82M | $-9.26M |
Cerevel Therapeutics Holdings Dividends
Explore Cerevel Therapeutics Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Cerevel Therapeutics Holdings News
Read the latest news about Cerevel Therapeutics Holdings, including recent articles, headlines, and updates.
ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”).
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / April 25, 2025 / A class action was filed against against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company"), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer") on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act. If you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) for violations of the federal securities laws on behalf of investors who: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”) and thus were damaged by Defendants' violations of Section 10(b) of the Exchange Act (the “Fraud Claim Class”); (b) held shares of Cerevel as of the January 8, 2024 record date (“Record Date”) and were entitled to vote on the merger of Cerevel and AbbVie Inc. (“AbbVie”) and thus were damaged by Defendants' violations of Section 14(a) of the Exchange Act (the “Proxy Claim Class”); and (c) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act (the “Insider Trading Claim Class,” and collectively with the Fraud Claim Class and the Proxy Claim Class, the “Class”).
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. SO WHAT:If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
CERE Stockholders with Large Losses Can Lead the Class Action on Behalf of Former Investors of Cerevel Therapeutics Holdings, Inc. – Contact Robbins LLP for Information
SAN DIEGO, CA / ACCESS Newswire / April 22, 2025 / Robbins LLP reminds stockholders that a class action was filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company"), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer") on behalf of a class (the "Class") consisting of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel (NASDAQ:CERE) during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit
NEW YORK , April 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023. A class action lawsuit has already been filed.
ROSEN, A LEADING NATIONAL FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025.
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / The Rosen Law Firm, P.A. WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023.
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options A class action was filed against against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company"), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer") on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act. If you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
LOWEY DANNENBERG, P.C. is Investigating Claims on Behalf of California Cryobank LLC Customers Who May Have Been Harmed by a Recent Data Breach
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg, P.C. is investigating potential claims regarding a data breach at California Cryobank LLC that occurred between April 20 – 22, 2024. To contact us regarding this investigation, please visit our website HERE and complete the form to speak with an attorney.
Lowey Dannenberg Notifies Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) for violations of the federal securities laws on behalf of investors who purchased or acquired Maravai common stock between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”).
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders
Robbins LLP is Investigating Allegations that Cerevel Therapeutics Holdings, Inc. (formerly CERE) Misled Investors Relating to the Company's October 16, 20
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CERE.